Hematopoietic Stem Cells Transplantation Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Hematopoietic Stem Cells Transplantation Market Report Segments the Industry Into by Transplant Type (Autologous Transplant, and More), Stem Cell Source (Peripheral Blood Stem Cell Transplant, and More), Indication (Leukemia, and More), End User (Transplant & Cellular-Therapy Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Hematopoietic Stem Cell Transplantation Market Size and Share

Hematopoietic Stem Cell Transplantation Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Hematopoietic Stem Cell Transplantation Market Analysis by Mordor Intelligence

The Hematopoietic Stem Cell Transplantation Market size is estimated at USD 3.74 billion in 2025, and is expected to reach USD 6.25 billion by 2030, at a CAGR of 10.79% during the forecast period (2025-2030).

Expanding indications beyond hematologic malignancies, the convergence of reduced-toxicity conditioning agents, and wider donor-matching networks are moving the therapy from niche to mainstream. Momentum is bolstered by the use of HSCT as a bridging option before chimeric antigen receptor T-cell infusions, while next-generation AI tools accelerate donor–recipient matching for ethnically diverse populations. North America keeps a leadership position due to reimbursement clarity and clinical-trial density, yet Asia-Pacific is delivering the fastest procedural growth as healthcare systems invest heavily in transplant centers. Competitive intensity remains moderate because of high infrastructure and accreditation hurdles, though automated cell-processing platforms and cloud-based registry analytics are starting to reset operating cost curves.

Key Report Takeaways

  • By transplant type, allogeneic procedures held 58.32% of the Hematopoietic stem cells transplantation market share in 2024, while the same segment is forecast to expand at 11.37% CAGR through 2030.
  • By stem cell source, peripheral blood accounted for 81.29% share of the Hematopoietic stem cells transplantation market size in 2024, whereas cord blood is projected to grow at 12.52% CAGR to 2030.
  • By indication, leukemia dominated with 34.65% revenue share in 2024; non-malignant blood disorders are advancing at a 13.24% CAGR over the forecast horizon.
  • By end user, transplant and cellular-therapy centers led with 45.19% share in 2024; academic and research institutes are poised for the fastest 14.51% CAGR through 2030.
  • By geography, North America commanded 41.88% of the Hematopoietic stem cells transplantation market in 2024, while Asia-Pacific is set to grow at 15.23% CAGR to 2030.

Segment Analysis

By Transplant Type: Allogeneic Dominance Drives Innovation

Allogeneic procedures captured 58.32% of the Hematopoietic stem cells transplantation market in 2024 and are tracking an 11.37% CAGR to 2030, signaling enduring reliance on donor-sourced grafts. Orca-T posted superior Phase 3 survival and relapse outcomes versus standard care and showcases how selective graft engineering can cut graft-versus-host disease, further enlarging adoption. The segment benefits from registry growth, improved HLA-typing accuracy, and prophylaxis innovations like post-transplant cyclophosphamide.

Momentum is also evident in haploidentical protocols, where partial matches from relatives expand donor pools and reduce search times. A Johns Hopkins study documented 95% overall survival and 88% cure rates in sickle-cell disease using reduced-intensity, haploidentical bone-marrow transplantation. These outcomes reinforce the competitive edge of allogeneic grafts even as autologous approaches face substitution risk from CAR-T therapies. The Hematopoietic stem cells transplantation market therefore remains anchored by allogeneic innovation, with process automation and targeted conditioning poised to enhance margin profiles.

Market Share by Transplant Type
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Stem Cell Source: Peripheral Blood Leadership with Cord Blood Acceleration

Peripheral-blood procedures retained 81.29% share of the Hematopoietic stem cells transplantation market in 2024 due to rapid engraftment and donor convenience. Growth, however, is tilting toward cord-blood transplants, which are advancing at a 12.52% CAGR. The 2024 Omisirge approval shortened median neutrophil recovery to 12 days from 22 days for standard cord units, proving commercial viability for expanded grafts.

China has performed nearly 40,000 therapeutic cord-blood infusions, including 900 thalassemia transplants with 99% survival, illustrating how large-scale cord banking can propel the Hematopoietic stem cells transplantation market. Haplo-cord combinations now merge partial sibling grafts with cord units to solve cell-dose limitations in adults. Bone-marrow harvests remain relevant for indications requiring heightened graft-versus-leukemia effects, although their share continues to decline. Next-generation expansion platforms such as UM171 may further de-risk cord-blood usage in heavier patients.

By Indication: Leukemia Leadership with Non-Malignant Disorders Emerging

Leukemia accounted for 34.65% of total procedures in 2024, underlining its status as the largest revenue generator within the Hematopoietic stem cells transplantation market. Early-stage risk profiling now optimizes transplant timing, enhancing event-free survival. Consistent evidence supports tandem transplants and MRD-guided conditioning to curb relapse.

Non-malignant blood disorders are the fastest-growing indication, posting 13.24% CAGR as curative transplants for sickle-cell disease and thalassemia become routine. Gene-editing breakthroughs like exa-cel underscore curative potential, yet HSCT retains an edge on durability in many centers. Lymphoproliferative disorders hold moderate share, but competitive pressure from CAR-T products could temper future HSCT demand. Overall, the expanding indication mix keeps the Hematopoietic stem cells transplantation market diversified and resilient.

Market Share by Indication
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Transplant Centers Lead with Academic Institutes Accelerating

Dedicated transplant centers held 45.19% share in 2024, benefiting from multidisciplinary teams and economies of scale that align with accreditation metrics. Many of these centers integrate cell-processing suites, helping them capture downstream revenue and strengthen bargaining clout with payers. Standardization initiatives, such as the Joint Accreditation Committee for ISCT and EBMT, reinforce their dominant market position.

Academic institutions, advancing at 14.51% CAGR, are spearheading early-phase trials for antibody-based conditioning and graft engineering. The FDA authorization of Ryoncil for steroid-refractory acute GVHD stemmed directly from multicenter academic data sets asgct.org. Research-driven patient inflows accelerate adoption of novel regimens before community roll-out, driving above-market growth. Smaller multi-specialty hospitals remain constrained by capital investment requirements and staffing gaps, keeping the Hematopoietic stem cells transplantation market concentrated in high-volume hubs.

Geography Analysis

North America controlled 41.88% of the Hematopoietic stem cells transplantation market in 2024 thanks to favorable reimbursement mechanisms, a dense transplant-center network, and continuous trial activity. Medicare’s alignment of transplant payments with Diagnosis-Related Group revisions has improved provider liquidity, encouraging volume growth. The region also accounts for a sizable portion of global autologous transplants because of multiple myeloma prevalence.

Europe follows closely, backed by standardized EBMT guidelines and cross-border donor coordination. Adoption of treosulfan conditioning in Germany and Italy demonstrates how regulatory convergence accelerates technology diffusion. However, tighter budget caps in certain markets slow procedure growth compared with North America.

Asia-Pacific stands out with a 15.23% CAGR and is quickly narrowing the procedural-density gap. China’s National Health Commission has increased public funding for transplant infrastructure, while India introduced bundled-payment pilots that include long-term follow-up. New cord-blood labs in the United Arab Emirates rose from 2 to 8 after regulatory changes in 2020, showing how policy shifts can fast-track capacity. South America and the Middle East & Africa remain nascent but are positioned for double-digit growth as insurance coverage widens. Combined, these regional dynamics underscore the strategic importance of geographical diversity for companies targeting the Hematopoietic stem cells transplantation market.

Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The Hematopoietic stem cells transplantation market is consolidated, with high barriers tied to capital-intensive GMP facilities and stringent regulatory oversight. Lonza’s USD 1.2 billion purchase of Roche’s Vacaville site expands integrated manufacturing offerings and secures long-term client contracts. Miltenyi Biotec struck a multi-year supply pact with Autolus Therapeutics to provide CliniMACS cell-processing hardware, locking in downstream consumable revenue.

Product innovation remains a differentiator. The FDA clearance of Omisirge, the first ex vivo expanded cord-blood graft, gives Gamida Cell a competitive edge, while Orca-T’s selective allograft architecture could redefine GVHD management. Automated closed-system technologies reduce labor costs and contamination risks, allowing smaller entrants to compete on efficiency. AI-powered donor-matching software licensed by registries in the United States and Germany is reducing search times and could become a standard add-on service.

Strategic partnerships help firms bridge capability gaps. Contract development and manufacturing organizations collaborate with hospital networks to embed processing suites inside transplant centers, shortening logistics. Companies also co-develop companion diagnostics for pharmacogenomic-based conditioning, reinforcing stickiness across the transplant continuum. Despite emerging threats from gene-editing and CAR-T modalities, synergies in sequential or combination therapy are driving cross-technology alliances that keep the competitive field active.

Hematopoietic Stem Cell Transplantation Industry Leaders

  1. STEMCELL Technologies, Inc.

  2. Pluristem Therapeutics, Inc.

  3. Merck KGaA

  4. ScienCell Research Laboratories, Inc.

  5. Lonza Group

  6. *Disclaimer: Major Players sorted in no particular order
Hematopoietic Stem Cells Transplantation Market
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • March 2025: Orca Bio announced positive results from its pivotal Phase 3 study of investigational Orca-T compared to allogeneic stem cell transplant for hematologic malignancies, demonstrating superior outcomes that could reshape treatment paradigms for high-risk patients requiring transplantation.
  • March 2025: Garuda Therapeutics raised USD 50 million in funding and appointed a new CEO to advance its stem cell therapy pipeline, reflecting continued investor confidence in next-generation transplant technologies.
  • February 2025: Johns Hopkins Kimmel Cancer Center published breakthrough results in The New England Journal of Medicine Evidence demonstrating 95% survival and 88% cure rates using reduced-intensity haploidentical bone marrow transplantation for sickle cell disease.
  • February 2025: IN8bio presented positive Phase 1 data at TCT 2025 for its allogeneic gamma-delta T cell therapy INB-100, showing no relapses in AML patients after median follow-up of 20.1 months with 90.9% one-year progression-free survival.
  • January 2025: FDA approved Grafapex (treosulfan) in combination with fludarabine for allogeneic hematopoietic stem cell transplantation in patients aged one year and older with AML or MDS, providing a new conditioning regimen option with improved safety profile.

Table of Contents for Hematopoietic Stem Cell Transplantation Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Global Incidence of Hematologic Malignancies
    • 4.2.2 Advancements in Conditioning Regimens
    • 4.2.3 Increased Investment in Regenerative Medicine and Cell Therapy R&D
    • 4.2.4 Expansion of International Donor Registries and HLA-Typing Technologies
    • 4.2.5 Emergence of CAR-T Bridging Strategies
    • 4.2.6 Integration of AI and Machine Learning in Donor-Recipient Matching
  • 4.3 Market Restraints
    • 4.3.1 High cost of HSCT Procedures and Long-Term Post-Transplant Care
    • 4.3.2 Limited Availability of Matched Donors
    • 4.3.3 Growing Adoption of CAR-T and Other Cell Therapies
    • 4.3.4 Manufacturing and Regulatory Bottlenecks in GMP-Compliant Cell Therapy Facilities
  • 4.4 Regulatory Landscape
  • 4.5 Porter’s Five Forces Analysis
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitute Products
    • 4.5.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value in USD)

  • 5.1 By Transplant Type
    • 5.1.1 Autologous Transplant
    • 5.1.2 Allogeneic Transplant
  • 5.2 By Stem Cell Source
    • 5.2.1 Peripheral Blood Stem Cell Transplant
    • 5.2.2 Bone Marrow Transplant
    • 5.2.3 Cord Blood Transplant
  • 5.3 By Indication
    • 5.3.1 Leukemia
    • 5.3.2 Lymphoproliferative Disorders
    • 5.3.3 Multiple Myeloma & Plasma-Cell Dyscrasias
    • 5.3.4 Non-Malignant Blood Disorders
  • 5.4 By End User
    • 5.4.1 Transplant & Cellular-Therapy Centers
    • 5.4.2 Academic and Research Institutes
    • 5.4.3 Multi-Specialty Hospitals & Clinics
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Talaris Therapeutics
    • 6.3.2 Thermo Fisher Scientific
    • 6.3.3 STEMCELL Technologies
    • 6.3.4 Pluristem Therapeutics
    • 6.3.5 Merck KGaA
    • 6.3.6 Lonza Group
    • 6.3.7 Sartorius CellGenix
    • 6.3.8 ScienCell Research Laboratories
    • 6.3.9 ThermoGenesis Holdings
    • 6.3.10 Novartis AG
    • 6.3.11 Bristol Myers Squibb
    • 6.3.12 Gilead Sciences
    • 6.3.13 Sanofi S.A.
    • 6.3.14 Takeda
    • 6.3.15 GAMIDA Cell
    • 6.3.16 Bluebird bio
    • 6.3.17 Miltenyi Biotec
    • 6.3.18 Fujifilm Cellular Dynamics
    • 6.3.19 Cryoport Systems

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Hematopoietic Stem Cell Transplantation Market Report Scope

As per the scope of the report, hematopoietic stem cell transplantation is a procedure that involves the intravenous infusion of autologous or allogeneic stem cells to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective. The hematopoietic stem cell transplantation market is segmented by Type (Autologous Transplant and Allogenic Transplant), Indication (Leukemia, Lymphoproliferative Disorders, and Non-Malignant Disorders), Application (Bone Marrow Transplant, Peripheral Blood Stem Cell Transplant, and Cord Blood Transplant), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Transplant Type Autologous Transplant
Allogeneic Transplant
By Stem Cell Source Peripheral Blood Stem Cell Transplant
Bone Marrow Transplant
Cord Blood Transplant
By Indication Leukemia
Lymphoproliferative Disorders
Multiple Myeloma & Plasma-Cell Dyscrasias
Non-Malignant Blood Disorders
By End User Transplant & Cellular-Therapy Centers
Academic and Research Institutes
Multi-Specialty Hospitals & Clinics
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Transplant Type
Autologous Transplant
Allogeneic Transplant
By Stem Cell Source
Peripheral Blood Stem Cell Transplant
Bone Marrow Transplant
Cord Blood Transplant
By Indication
Leukemia
Lymphoproliferative Disorders
Multiple Myeloma & Plasma-Cell Dyscrasias
Non-Malignant Blood Disorders
By End User
Transplant & Cellular-Therapy Centers
Academic and Research Institutes
Multi-Specialty Hospitals & Clinics
By Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is driving growth in the Hematopoietic stem cells transplantation market?

Rising incidence of blood cancers, reduced-toxicity conditioning regimens, expanding donor registries and strong investment in cell-therapy infrastructure together push the market toward a 10.79% CAGR through 2030.

How large is the Hematopoietic stem cells transplantation market in 2025?

The Hematopoietic stem cells transplantation market size is valued at USD 3.74 billion in 2025 and is forecast to reach USD 6.25 billion by 2030.

Which segment holds the largest share of the Hematopoietic stem cells transplantation market?

Allogeneic transplants lead with 58.32% share in 2024, driven by improved donor-matching technologies and GVHD prophylaxis advances.

Where is the fastest regional growth occurring?

Asia-Pacific shows the fastest regional momentum with a projected 15.23% CAGR, supported by infrastructure investments and growing insurance coverage.

What recent regulatory approvals have influenced the market outlook?

Key approvals include Grafapex treosulfan conditioning, Omisirge expanded cord-blood grafts and Ryoncil for steroid-refractory acute GVHD, each broadening patient eligibility and improving outcomes.

How does HSCT compete with CAR-T and gene therapies?

Although CAR-T offers alternative autologous options, HSCT retains advantages in durability and curative potential for a broad range of hematologic diseases, and is increasingly used as a bridging or complementary therapy.

Page last updated on: June 20, 2025

Hematopoietic Stem Cell Transplantation Market Report Snapshots

Compare market size and growth of Hematopoietic Stem Cell Transplantation Market with other markets in Healthcare Industry